Is methylprednizalone a predisposing factor for bacterial and fungal infections in critical patients due to covid-19?

Yıl 2021, Cilt: 3 Sayı: 1, 21 - 24, 15.04.2021

Mine Altınkaya Çavuş , Hafize Sav

Öz

Aim: The COVID -19 outbreak was first seen in Wuhan, China\'s Hubei province. Lung infections caused by COVID-19; It can progress to severe ARDS (acute respiratory distress syndrome) with a high mortality.For ARDS patients, methylprednisolone (1-2 mg / kg per day) is recommended to be as short as possible
Methods:All patients with a diagnosis of covid-19 over the age of 18 who were hospitalized in the pandemic intensive care unit between March 2020 and September 2020 were retrospectively screened.Patients; demographic data, hospitalization APACHE II scores, length of stay in hospital and intensive care, laboratory values (d-dimer, creatinine, CRP (C reactive protein)), culture results, mortality and morbidity, mechanical ventilator needs. On the first day of intensive care admissions, methylprednizalone was added to the treatment intravenously at 0.5 mg/kg/day for 5 days.
Results:A total of 201 patients hospitalized in adult level 3 intensive care were included in the study. All patients were PCR positive. 44.8% of the patients were female (n: 90), 55.2% were male (n: 111). Blood, urine and ETA cultures; there was no statistically significant relationship between gender, IMV need, mortality and prednol use.
Conclusion: COVID-19 is a viral infectious disease that manifests mainly as fever and pneumonia. Corticosteroid therapy; in addition, it includes the following risks: hyperglycemia, poor wound healing, psychosis, pancreatitis, and prolonged muscle weakness in impaired functional status in a meta-analysis published in 2012, nine randomized controlled trials, 1001 patients were included. Consequently, the use of corticosteroids did not decrease mortality.

Anahtar Kelimeler

methylprednizalone, bacterial and fungal infections, covid-19

Kaynakça

• 1. Lu R, Zhao X, Li J, Niu P, Yang B, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74.
• 2. Del Rio C, Malani PN. COVID-19-New insights on a rapidly changing epidemic. J Am Med Assoc. 2020:28.
• 3.Coronavirus disease 2019 (COVID-19) situation report e 45. https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125
• 4. Guan WJ, Ni ZY, Hu Y et al. China medical treatment expert group for covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020.
• 5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus disease in China. N Engl J Med. 2020.
• 6. Fauci AS, Lane HC, Redfield RR. Covid-19 navigating the uncharted. N Engl J Med, 2020.
• 7. Kumar A, Liang B, Aarthy M, et al. Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease, ACS Omega3. Journal Pre-proof. 2018;18132-41.
• 8. Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies, Chinese Journal of Pathology. 2020;49:9.
• 9. Pairu J, Triveni GS, Manohar A. The study of serum calcium and serum magnesium in pregnancy induced hypertension and normal pregnancy. Int J Reprod Contracept Obstet Gynecol. 2015;4:30-4.
• 10. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Inten Care Med. 2020;46:846-8.
• 11. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348:683-93
• 12. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242-8.
• 13. Garcia-Vidal, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J. 2007;30:951-6.
• 14. Shafiq M, Mansoor MS, Khan AA, Sohail MR, Murad MH. Adjuvant steroid therapy in community-acquired pneumonia: a systematic review and meta-analysis. J Hosp Med. 2013; 8:68-75.
• 15. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the Treatment of Community-Acquire Pneumonia in Adults: A Meta-Analysis. PLoS One. 2012;7.